Effisayil™ 1: a Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
To evaluate efficacy, safety, and tolerability of spesolimab (BI 655130) compared to placebo in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.
Epistemonikos ID: 4422b9ce9f353f9d7c8e25ecd276a47333afe14c
First added on: May 21, 2024